ELOX - Company ID 0001035354
Eloxx Pharmaceuticals, Inc. (ELOX) reported net income of -$6.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$6.00M | -90.7% |
| FY 2024 | -$3.14M | +81.6% |
| FY 2023 | -$17.05M | +52.7% |
| FY 2022 | -$36.06M | +46.0% |
| FY 2021 | -$66.73M | -93.0% |
| FY 2020 | -$34.58M | +32.0% |
| FY 2019 | -$50.87M | -7.8% |
| FY 2018 | -$47.19M | -122.4% |
| FY 2017 |
Eloxx Pharmaceuticals, Inc. (ELOX) reported net income of -$6.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, Eloxx Pharmaceuticals, Inc.'s net income grew from -$7.27M to -$6.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$21.21M |
| -115.4% |
| FY 2016 | -$9.85M | -53.7% |
| FY 2015 | -$6.41M | +30.6% |
| FY 2014 | -$9.23M | -50.7% |
| FY 2013 | -$6.12M | -20.9% |
| FY 2012 | -$5.07M | +30.3% |
| FY 2011 | -$7.27M | - |